Genomic Testing

Kenneth G. Nepple, MD, discusses a quality improvement initiative focused on identifying patients with prostate cancer who may be eligible for genetic testing.

The PROSTOX ultra test identifies men with localized prostate cancer who are at a higher risk of developing late GU toxicity from radiation, helping to inform treatment decisions.

Patients with GG1 disease and a high genomic classifier score had a significantly higher risk of disease progression.

The approval is supported by data from the phase 3 AMPLITUDE trial.

The PROSTOX ultra test can predict which patients with localized prostate cancer are at a higher risk of GU toxicity from SBRT.

Veda Giri, MD, highlights her recent review publication on the current state of germline testing in prostate cancer.

Hong Truong, MD, MS, details key findings on referrals for genetic counseling among patients with kidney cancer who meet the criteria for genetic evaluation.

Rana R. McKay, MD, FASCO, outlines findings from a study looking at the somatic, germline, and immunologic landscapes of UTUC and UCB tumors.

Hong Truong, MD, MS, highlights key findings on genetic counseling rates in patients with kidney cancer.

The findings were derived from the multicenter, prospective, phase 3 STAMPEDE trial.

Kathryn H. Gessner, MD, PhD, outlines the clinical scenarios in which she finds genomic testing most useful.

The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.

“I truly think genetic testing should be incorporated as a part of daily care in prostate cancer,” says Joy Maulik, CRNP.

Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.

WNT9B E152K was associated with a 2.5-fold increase in the risk of prostate cancer and reached genome-wide significance.

"[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.

Test your knowledge of these often-overlooked but essential aspects of genetic and genomic testing.

The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.

Test your knowledge of this quiz on the Canadian Urological Association's recommendations for genomic profiling of tumors in prostate cancer.

Test your knowledge of this quiz on the Canadian Urological Association's recommendations for germline genetic testing in prostate cancer management.

Sieber shares his thoughts on the potential for universal genetic testing to become a standard of care practice for patients with prostate cancer.

“Our study highlights the potential of epigenomic profiling from a simple blood draw to provide a real-time, non-invasive readout of PSMA expression that corresponds with treatment response," says Jacob E. Berchuck, MD.

"I'm hopeful that the decisions are more informed in terms of actual science," says Daniel Kwon, MD.

“Before long, what we do, how we do it, and when we do it might solely be based off of those genetic testing results,” says Tim Richardson, MD.